The claims language gives Elute broad protection for the first combination drug/device product on the market capable of delivering an antibiotic for up to eight weeks to eradicate infection and grow new bone.
| |
| [31-January-2018] |
| SALT LAKE CITY, Jan. 31, 2018 /PRNewswire/ -- Elute, an emerging leader in developing a new class of polymer-controlled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections, announced today that the Company has received a notice of allowance from the United States Patent & Trademark Office on January 26th for its invention of “Implantable Devices for Bone or Joint Defects”. “We are very pleased to receive this notification,” said Ashok C. Khandkar, Ph.D., Chief Executive Officer of Elute. “The scope of this patent enables us to maintain our advantage and protect the proprietary aspects of our technologies, as we move forward towards the clinical introduction of our products,” stated Dr. Khandkar. The claims language gives Elute broad protection for the first combination drug/device product on the market capable of delivering an antibiotic for up to eight weeks to eradicate infection and grow new bone. “This allowance is key to our strategy of aggressively pursuing patent coverage and enhancing our value,” said Dennis B. Farrar, Executive Chairman and co-founder of Elute. About Elute, Inc.™ Company Contact: View original content:http://www.prnewswire.com/news-releases/elute-receives-notification-of-issuance-of-key-patent-from-the-us-patent--trademark-office-300590821.html SOURCE Elute, Inc. |
